Financial Summary for the First Quarter of Fiscal Year Ending March 2027【Japan GAAP】 (Unaudited, Non-Consolidated)

Performance Overview

Japan Tissue Engineering Co., Ltd. reported consolidated sales of 76.6 billion yen (YoY +80.3%), operating income of 5.9 billion yen (YoY +66.4%), and net income of 5.2 billion yen (YoY +21.7%) for the first quarter of fiscal year ending March 2027. The strong performance was driven by the robust growth of the medical business segment. The sales increase was mainly due to contributions from regenerative medical products and laboratory site operations, with cost control measures also improving profit margins. Compared to the same period last year, significant growth was achieved, enhancing expectations for future expansion.

Outlook and Impact on Shareholders

Continued growth in sales and profits is anticipated through expansion of the medical business and the launch of new products. The company plans to strengthen R&D investments to meet increasing demand in the regenerative medicine field. Shareholders can expect increased dividends and stock price appreciation associated with the profit growth, though ongoing investments to support business expansion may also impact financials. In the medium to long term, the company aims to establish a stable revenue base and enhance shareholder returns.